However, clinical studies using ruboxistaurin, a selective PKC β inhibitor, for treatment of painful diabetic neuropathy did not achieve significance [ 127 ].
1
—
—
However, clinical studies using ruboxistaurin, a selective PKC β inhibitor, for treatment of painful diabetic neuropathy did not achieve significance [ 127 ].